- Home
- MAS vs PODD Comparison
MAS vs PODD Comparison
Compare MAS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAS | PODD |
|---|---|---|
| Founded | 1929 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 17.0B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MAS | PODD |
|---|---|---|
| Price | $65.39 | $240.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | $75.86 | ★ $358.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.0M |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 2.66 | N/A |
| EPS | ★ 3.86 | 3.48 |
| Revenue | ★ $7,562,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | $2.80 | $24.33 |
| Revenue Next Year | $3.38 | $19.33 |
| P/E Ratio | ★ $17.72 | $70.10 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $56.55 | $230.08 |
| 52 Week High | $79.19 | $354.88 |
Technical Indicators
Market Signals| Indicator | MAS | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 39.44 |
| Support Level | $64.17 | $238.68 |
| Resistance Level | $66.21 | $299.75 |
| Average True Range (ATR) | 2.09 | 8.49 |
| MACD | -1.22 | 0.86 |
| Stochastic Oscillator | 3.34 | 13.33 |
Price Performance
Historical ComparisonAbout MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5 billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3 billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.